Il trattamento dell’Ipertensione nel paziente diabetico Francesco Vittorio Costa Università degli Studi di Bologna Diabete e ipertensione 1. Diabete+ipertensione: dimensione del problema 2. La terapia antipertensiva produce vantaggi nei diabetici? 3. Quale la PA da raggiungere nei diabetici? 4. Quali antipertensivi utilizzare? Prevalence of Hypertension in Type 2 Diabetes Normoalbuminuria (n = 323) Macroalbuminuria (n = 75) Microalbuminuria (n = 151) Total (n = 549) 100 90 93 80 71 Prevalence of hypertension 50 (%) 0 Hypertension defined as BP 140/90 mm Hg. Tarnow L et al. Diabetes Care 1994;17:1247-1251. L’EVIDENZA: DM + HT È PERICOLOSA Relative Risk of DM + HTN Diabetes + HTN versus Diabetes • Neuropathy 1.6 • Nephropathy 2.0 • Retinopathy 2.0 • Stroke 4.0 • CHD 3.0 . Mortality 2.0 CV Mortality Risk CV Mortality Risk Doubles with Each 20/10 mm Hg BP Increment 8 7 6 5 4 3 2 1 0 115/75 135/85 155/95 175/105 SBP/DBP (mm Hg) Lewington S, et al. Lancet. 2002; 60:1903-1913.JNC VII. JAMA. 2003. Terapia dell’ipertensione e diabete 2- la terapia antiipertensiva produce vantaggi nei diabetici ? Confronto con placebo Risk reduction in meta-analyses of placebo RCTs. Diabetic hypertensives Risk reduction % 0 Stroke CHF CHD -10 -20 -30 -40 -50 -60 * * ** * * * -70 * * * *p<0.05 -80 -90 Death * Psaty et al JAMA 1997;277:739 BPLT Lancet 2000;356:1955 * Diuretics low dose high dose b-block. CCBs ACE-Is La terapia antipertensiva produce vantaggi nei diabetici ? Confronto con placebo SI La terapia antipertensiva riduce gli eventi in maniera significativa nei pazienti diabetici Terapia dell’ipertensione e diabete Risultati ottenuti nel controllo pressorio dei pazienti diabetici Awareness, treatment and control of hypertension according to diabetes status. aP<0.05 vs. nondiabetes mellitus (non- DM), BP<0.05 vs. known-DM. Diabetes Metab J 2014;38:51-57 Failure to Intensify Antihypertensive Treatment by Primary Care Providers: A Cohort Study in Adults with Diabetes Mellitus and Hypertension In this highly adherent cohort of adults with diabetes and hypertension, failure to intensify treatment for high blood pressure was a common problem: primary care providers intensified treatment at only 13% of visits where blood pressure was unequivocally elevated. J Gen Intern Med 2008, 23(5):543–50 Terapia dell’ipertensione e diabete 1. Diabete+ipertensione: dangerous duo 2. La terapia antipertensiva produce vantaggi nei diabetici ? 3. Quale la PA da raggiungere nei diabetici? 4. Quali antipertensivi utilizzare? Events per 1000 patient yrs UKPDS Event Rates for Select Endpoints With Tight vs Less Tight Blood Pressure Control 80 70 P=0.005 Tight (n=758) mean achieved BP 144/82 mmHg 60 Less tight (n=390) mean achieved BP 154/87 mmHg 50 40 30 P=0.02 20 P=0.01 P=0.009 10 0 Any diabetesrelated endpoint Diabetesrelated death UKPDS Group. BMJ. 1998;317:703–713. Stroke Microvascular complications HOT Diabetic Subgroup Reduction in Cardiovascular Events P=0.005 25 Achieved† Achieved† # of patients with diabetes diastolic BP systolic diastolic (mmHg) BP BP (mmHg) (mmHg) 90 143.7 85.2 501 85 141.4 83.2 501 80 139.7 81.1 499 †mean of all blood pressures for all study patients in BP subgroups from 6 months of follow-up to end of study *Includes all myocardial infarction, all strokes, and all other cardiovascular deaths Hansson L, et al. Lancet. 1998;351:1755–1762. 20 Number of events* per 1000 patient-yrs Target 15 10 5 0 Change from baseline (mmHg) UKPDS Effetto sugli eventi del controllo stretto vs. meno stretto di glicemia e di PA † UKPDS Group. BMJ. 1998;317:703–713. UKPDS: NNT per i diversi end-point (controllo PA vs controllo glicemia) End point NNT1 NNT2 9 31 Mortalità correlata al diabete 16 112 Mortalità totale 23 125 IMA 23 46 ICTUS 23 169 Complicanze microvascolari 17 42 Qualunque complicanza del diabete NNT1 = “ tight blood pressure control” NNT2 = “tight glicemic control” (da Snow et Al, Ann Intern Med 2003) Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes (ADVANCE) Hazard Ratios for Events, According to Blood-Pressure–Lowering Study Group The New England Journal of Medicine September 24, 2014. Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes (ADVANCE) Hazard Ratios for Events, According to Glucose-Control Study Group. The New England Journal of Medicine September 24, 2014. Terapia dell’ipertensione e diabete Ci sono vantaggi addizionali se il trattamento antiipertensivo è più aggressivo? SI A una maggior riduzione pressoria corrisponde una maggior riduzione degli eventi FINO A CHE VALORI SCENDERE? Cosa dicono le Linee guida? Blood Pressure Targets in Subjects With Type 2 Diabetes Mellitus/Impaired Fasting Glucose Observations From Traditional and Bayesian RandomEffects Meta-Analyses of Randomized Trials “In patients with type 2 diabetes mellitus/impaired fasting glucose/impaired glucose tolerance, a systolic BP treatment goal of 130 to 135 mm Hg is acceptable. However, with more aggressive goals (<130mm Hg), the risk of stroke continued to fall, but there was no benefit on the risk of other macrovascular or microvascular (cardiac, renal and retinal) events, and the risk of serious adverse events even increased. (Circulation. 2011;123:2799-2810.) C’è un aumento di rischio per pressioni più basse? Safety and Efficacy of Low Blood Pressures Among Patients With Diabetes Subgroup Analyses From the ONTARGET Proportion of Outcome Events by Achieved SBP, Divided Into Deciles JACC Vol. 59, No. 1, 2012 Terapia dell’ipertensione e diabete 1. Diabete+ipertensione: dangerous duo 2. La terapia antipertensiva produce vantaggi nei diabetici ? 3. Quale la PA da raggiungere nei diabetici? 4. Quali antipertensivi utilizzare? Effetti degli antipertensivi sul metabolismo glucidico Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis Lancet 2007; 369: 201–07 22 clinical trials, 143 153 patients. Initial diuretic used as referent agent. Size of squares (representing the point estimate for each class of antihypertensive drugs) is proportional to number of patients who developed incident diabetes. Tutti i sartani producono lo stesso effetto sul metabolismo glucidico? Effects of Telmisartan & Losartan in Patients with metabolic syndrome FPGlucose FPInsulin HOMA IR HbA1c Change from baseline (%) 0 -10 P<0.05 P<0.05 P<0.06 -20 P<0.05 Telmisartan (n=20) Losartan (n=20) -30 Vitale et al. Cardiovasc Diabetol. 2005;15:6. 30 Effetti di Telmisartan e Eprosartan sui lipidi plasmatici Total cholesterol LDL-cholesterol Triglycerides Change from baseline (mg/dL) 0 -5 -10 * -15 -20 * -25 -30 -35 Eprosartan 600 mg (n=39) Telmisartan 40 mg (n=40) * * P<0.05 vs Eprosartan Study duration = 1 year Derosa et al. Hypertens Res 2004;27:457–464 Comparative Cardio-Metabolic Studies with Telmisartan Trial Patients N Duration (weeks) Comparator Agent(s) BP differential Improved Insulin Sensitivity Improved Lipid Profile Anti-oxidant/ Inflammatory Action Derosa 2004a HT, T2DM 119 52 Eprosartan/Placebo No (P yes) No Yes - Derosa 2004b HT, T2DM 116 52 Nifedipine GITS No No Yes - Vitale 2005 HT, MS 40 12 Losartan Yes? Yes - - Miura 2005 HT, T2DM 18 12 Candesartan/Valsartan No Yes Yes Yes Koulouris 2005 NT, T2DM 40 12 Ramipril No No No Yes Honjo 2005 HT, T2DM 38 12 Candesartan - Yes - - HT 37 6 Nisoldipine No? Yes - - Negro 2006a HT, T2DM 40 16 Amlodipine No Yes Yes - Negro 2006b HT, obese,IR 46 26 Irbesaratn No Yes Yes - Bahadir 2007 HT, MS 42 10 Losartan No? Yes? No - Derosa 2007 HT, T2DM 188 52 Irbesartan No Yes Yes Yes Sharma 2007 HT, obese 840 10 Valsartan HCTZ Yes No No - Benndorf 2006 Protezione dagli eventi e dal danno d’organo ACE- I vs altri Farmaci nei pazienti diabetici: effetti su tutti gli eventi cardiovascolari Study (95% CI) OR ABCD CAPPP FACET STOP2 UKPDS z=1.97 p=.05 Het. p=.0073 .1 .2 0.57 0.55 0.50 0.88 1.29 0.83 (0.69,1.00) 1 5 10 (modificato da Pahor et al. Diabetes Care 2000;23:888) LIFE: Diabetes – Total Mortality Proportion of patients, % 24 20 Atenolol Losartan 16 12 8 4 Adjusted Risk Reduction = 39%; p=0·002 Unadjusted Risk Reduction = 40%; p=0·001 0 0 6 12 18 24 30 36 Study Month LH Lindholm, et al Lancet 2002; 359:1004-1010 42 48 54 60 66 Effetti sugli eventi CV maggiori, morti CV e Mortalità Totale in Trial che Confrontano Regimi Basati su Classi Differenti di Antipertensivi in Pazienti con Diabete tipo 2 Comparison Trial N SBP/DBP diff. A vs B Major CV events RR (95% CI) CV death RR (95% CI) Total mortality RR (95% CI) CA vs D/bB INSIGHT 1302 +2/-1 0.99 (0.70-1.39) 0.93 (0.54-1.60) 0.75 (0.52-1.09) NORDIL 727 +3/0 1.21 (0.84-1.74) 0.24 (0.60-2.56) 1.15 (0.69-1.93) STOP-2 484 0/-2 0.91 (0.72-1.14) 0.80 (0.53-1.21) 0.82 (0.59-1.13) UKPDS 758 +1/+1 1.21 (0.89-1.63) 1.34 (0.88-2.05) 1.14 (0.83-1.55) CAPPP 572 0/0 0.64 (0.44-0.94) 0.51 (0.23-1.51) 0.57 (0.33-0.98) STOP-2 488 -1/0 0.86 (0.68-1.9) 0.93 (0.63-1.38) 0.90 (0.66-1.22) ABCD-NT 480 0/0 0.95 (0.74-1.21) 1.66 (0.71-3.89) 0.95 (0.52-1.75) ABCD-HT 470 0/0 0.60 (0.39-0.92) 0.55 (0.21-1.45) 0.78 (0.40-1.53) STOP-2 466 -1/+2 0.93 (0.74-1.21) 1.16 (0.76-1.78) 1.10 (0.79-1.54) 1195 -3/0 0.76 (0.58-0.98) 0.63 (0.42-0.95) 0.61 (0.45-0.84) 1146 -1/0 1.03 (0.81-1.32) 1.36 (0.89-2.07) 1.05 (0.78-1.42) ACEI vs D/bB ACEI vs CA AIIA vs D/b LIFE AIIA vs CA IDNT 0.1 Major CV events CV death Total mortality Zanchetti A et al., J Hypertens 2002 0.3 0.5 0.7 1.0 Favours drug class A 2.0 3.0 Favours drug class B Scegliere un sartano o un ACEI? Confronto efficacia ACE-I vs. sartani Sospensione del trattamento per reazioni avverse : ACEI vs Sartani Interruzioni del trattamento antipertensivo con monoterapia iniziale a 1 anno (Lombardia Data-base: n=445356) Diuretics 1.83 (1.81-1.85) Beta-blockers 1.64 (1.62-1.67) Alpha-blockers 1.23 (1.20-1.27) Calcium channel blockers 1.08 (1.06-1.09) ACE-inhibitors ARBs 0.5 0.92 (0.90-0.94) - 1.0 + 2.0 I sartani garantiscono i livelli migliori di persistenza Corrao G et al J Hypertens. 2008;26(4):819-24. Rischio relativo di non-persistenza a seconda del farmaco prescritto inizialmente +970% FV Costa et al, 2009 High Blood Press Cardiovasc Prev 2009; 16 (4): 1-10 NB: ogni 10 paz, che interrompono il sartano ce ne sono 21 che interrompono l’ACEI. Ogni 10 paz che interrompono Sartano+diur ce ne sono 24 che interrompono ACEI+diur Confronto sartani Ca-antagonisti Calcium Channel Blocker Compared With Angiotensin Receptor Blocker for Patients With Hypertension: A Meta-Analysis of Randomized Controlled Trials Heart failure P<0.06 J Clin Hypertens (Greenwich). 2014:1–8. Calcium Channel Blocker Compared With Angiotensin Receptor Blocker for Patients With Hypertension: A Meta-Analysis of Randomized Controlled Trials Stroke P<0.04 J Clin Hypertens (Greenwich). 2014:1–8. Number of Drugs Needed to Achieve a Goal BP Value in Pts with HBP and Diabetes 2.7 UKPDS (<85mmHg) 3.3 IDNT (<85mmHg) 3.4 RENAAL (<90mmHg) 2.8 ABCD (<75mmHg) 2.7 LIFE (<90mmHg) 3.6 MDRD (<92mmHg) 3.3 HOT (<80mmHg) 0 1 2 Drugs (Nr.) 3 4 5 Valutare nel tempo l’efficacia della terapia Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure: an analysisof the ONTARGET and TRANSCEND studies Adjusted HRs according to global effects of albuminuria, glycaemia and BP status. Diabetologia, DOI 10.1007/s00125-014-3330-9 July 2014 Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure: an analysisof the ONTARGET and TRANSCEND studies Conclusions/interpretation Patients who showed improvement to normoalbuminuria over 2 years were at lower risk of all-cause and cardiovascular mortality and of cardiovascular and renal events than those who deteriorated to microalbuminuria over time. Albuminuria over time was significantly better than glucose status and BP control in predicting mortality and both cardiovascular and renal outcomes in patients at a high cardiovascular risk. Reno-protective effects of renin–angiotensin system blockade in type 2 diabetic patients: Macroalbuminuria Microalbuminuria Diabetologia (2012) 55:566–578 Metanalisi (25425 paz) degli effetti di telmisartan e altri farmaci su proteinuria o albuminuria Take home message 1 - La associazione Diabete+ ipertensione è estremamente comune e particolarmente rischiosa - Una riduzione pressoria + stretta riduce maggiormente il rischio CV e lo riduce maggiormente rispetto al controllo + stretto della glicemia - Le percentuali di diabetici con PA ben controllata sono di gran lunga insufficienti e ciò dipende soprattutto da atteggiamenti terapeutici poco aggressivi - L’ottenimento di un buon controllo pressorio richiede quasi sempre terapie di associazione Take Home message 2 - ACE-i e ancor più i sartani non producono effetti sfavorevoli sul metabolismo glucidico . Il Temisartan migliora alcuni parametri metabolici glucidici e lipidici - ACE-i e sartani sono egualmente efficaci nel prevenire gli eventi ma i sartani garantiscono livelli più elevati di aderenza al trattamento - L’indice migliore per valutare l’efficacia del trattamento in termini di prevenzione degli eventi, è l’andamento della albuminuria - Telmisartan migliora l’albuminuria più degli altri sartani, più degli ACE-i e delle altre classi di farmaci Journal of Hypertension 2013, 31:1281–1357 Cosa dicono le Linee Guida?